Q Therapeutics, Inc. 4/A
4/A · Q Therapeutics, Inc. · Filed Feb 12, 2016
Insider Transaction Report
Form 4/AAmended
Q Therapeutics, Inc.[NONE]
BORST STEVEN JOHN
CFO & VP of Corp. Development
Transactions
- Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+400,000$280,000→ 2,750,274 totalExercise: $0.70From: 2016-09-08Exp: 2025-09-08→ Common Stock (400,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,850,274 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,950,274 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter.
- [F2]Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016.
- [F3]Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial.